| 刘佳,焦旸,何敏,等.低剂量放疗治疗重型/危重型新冠肺炎:获益还是风险？[J].中华放射医学与防护杂志,2023,43(9):747-751.Liu Jia,Jiao Yang,He Min,et al.Low-dose radiation therapy for severe/critical COVID-19: benefits or risks?[J].Chin J Radiol Med Prot,2023,43(9):747-751 |
| 低剂量放疗治疗重型/危重型新冠肺炎:获益还是风险？ |
| Low-dose radiation therapy for severe/critical COVID-19: benefits or risks? |
| 投稿时间：2023-02-20 |
| DOI：10.3760/cma.j.cn112271-20230220-00042 |
| 中文关键词: 新型冠状病毒 低剂量放射治疗 肺炎 |
| 英文关键词:COVID-19 Low-dose radiation therapy Pneumonia |
| 基金项目:江苏省卫生健康委员会重点科研项目（ZD2021053）；放射医学与辐射防护国家重点实验室科研创新项目（GZC00402）；江阴市科技局社会发展科技示范项目（JY0603A021014210005PB）；无锡市"双百"医疗人才计划项目（202014） |
|
| 摘要点击次数: 2088 |
| 全文下载次数: 767 |
| 中文摘要: |
| 新型冠状病毒肺炎（COVID-19）患者一旦发展成重型/危重型，肺部炎症因子风暴导致的呼吸衰竭就会成为患者的主要死亡原因。重型/危重型患者现有治疗方法疗效有限，低剂量放疗（LDRT）治疗重型/危重型COVID-19的临床应用在国外多个医学中心陆续开展，显示出良好的可行性和有效性，但其作用机制和最佳剂量尚未完全清楚。本文对LDRT治疗重型/危重型COVID-19的放射生物学机制、有效性、不良反应、治疗剂量等热点问题进行综述，以期更好地认识其临床获益和不良反应。 |
| 英文摘要: |
| Patients with severe or critical coronavirus disease 2019 (COVID-19) are at high risk of death primarily due to respiratory failure caused by the cytokine storm in pulmonary tissues. The treatment response of these patients remains limited. Recently, low-dose radiation therapy (LDRT) has been clinically adopted to treat severe or critical COVID-19 patients in multiple medical centers abroad, indicating high feasibility and effectiveness. However, the mechanism and optimal radiation dose are still incompletely clear. This paper reviews the radiobiological mechanism, effectiveness, adverse reactions, and radiotherapy dose of LDRT in the treatment of severe or critical COVID-19 patients, aiming to better understand the clinical benefits and adverse reactions of LDRT. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|